![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="900" height="501"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="250" height="148"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
Session 7: Next Generation Prostate Cancer Theranostics and Combination Therapies
29th Annual PCF Scientific Retreat: October 28, 2022 | 3:40 PM – 5:00 PM
Moderator: Ana Kiess, MD, PhD
Johns Hopkins University
Immunomodulation of Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate Response to Combination Therapies
Zachary Morris, MD, PhD
University of Wisconsin
Combination of PSMA-targeted Radiopharmaceutical Therapy and Immunotherapy for mCRPC
Shahneen Sandhu, MBBS
Peter MacCallum Cancer Centre, Australia
hK2 Targeted Radioimmunotheranostics for Prostate Cancer
David Ulmert, MD, PhD
University of California, Los Angeles